The Global Influenza Vaccine Market was valued at US$ 8.78 billion in 2023 and is projected to hit the market valuation of US$ 22.71 billion by 2032, growing at a CAGR of 11.07% during the forecast period from 2024 to 2032.
The influenza vaccine market is experiencing remarkable growth throughout the projected period. This growth can be primarily due to the increasing prevalence of influenza flu. Moreover, the market is poised to benefit from the rapid advancements in vaccine development, presenting lucrative opportunities for manufacturers. These technological breakthroughs are set to revolutionize the industry and drive further expansion.
The Request of this Sample Report Here- https://www.astuteanalytica.com/request-sample/influenza-vaccine-market
Seasonal influenza, commonly known as the flu, is an acute respiratory infection caused by influenza viruses. It is a widespread disease that affects people in all parts of the world. The World Health Organization (WHO) estimates that there are approximately a billion cases of seasonal influenza each year, with 3-5 million cases classified as severe illness. Influenza also leads to a significant number of respiratory deaths, ranging from 290,000 to 650,000 annually.
It is important to note that the burden of influenza-related deaths is particularly high in developing countries, with 99% of deaths in children under 5 years of age occurring in these regions. In the United States alone, the burden of influenza is substantial. During the 2022-2023 influenza season, the country witnessed an estimated 9 million flu illnesses, 4 million flu-related medical visits, 100,000 hospitalizations, and 5,000 deaths, according to the Centers for Disease Control and Prevention (CDC).
Vaccination is considered the most effective way to prevent influenza. It helps protect individuals from contracting the disease and reduces the severity of the symptoms if infection does occur. The flu vaccine is recommended for everyone aged 6 months and older. Given the significant demand for effective influenza vaccines, the market for these vaccines is experiencing notable growth. The increasing prevalence of influenza flu and the urgent need for prevention drive the market expansion.
Exploring the Power and Potential of the Influenza Vaccine Market
The effectiveness of influenza vaccines plays a crucial role in shaping market dynamics and public perception. Preliminary data suggests that the 2022-2023 flu vaccine was 68% effective against pediatric hospitalization, a statistic that significantly influences public trust and acceptance of the vaccine.
The Centers for Disease Control and Prevention (CDC) has established various organizations like the US Flu VE Network and the VISION Vaccine Effectiveness Network to evaluate and communicate vaccine efficacy. These networks play a vital role in assessing and disseminating information about the vaccine’s effectiveness, thereby impacting public trust and vaccine uptake.
Globally, influenza has a stark impact, with 99% of deaths in children under 5 years of age with influenza-related lower respiratory infections occurring in developing countries. This alarming statistic highlights the urgent need for enhanced vaccine accessibility and coverage in these regions. The expansion of the influenza vaccine market and targeted public health initiatives can address this need and contribute to reducing the burden of influenza-related illnesses and deaths.
Symptomatically, influenza presents with fever, cough, sore throat, and fatigue, typically lasting about a week. However, in the 2022-2023 season, only 41.9% of U.S. children and adolescents had received their annual influenza vaccination by the end of November, compared to higher rates in previous years. This lower vaccination rate among hospitalized children, combined with the season’s high severity, particularly for kids, indicates a potential market gap and an opportunity for increased vaccination campaigns.
Technological Advancements in Vaccine Development Unleash New Possibilities for Key Players
The global influenza vaccine market is experiencing significant growth due to rapid technological advancements in vaccine development. These advancements are transforming the production process, moving away from traditional egg-based methods to more innovative approaches such as cell culture and recombinant DNA technologies. This shift offers several advantages, including faster production times and potentially greater vaccine effectiveness.
Investments in cell-based vaccine manufacturing highlight the importance of this trend. For example, the U.S. Department of Health and Human Services invested over US$ 1 billion in 2019 for the development of cell-based influenza vaccine technology. This shift is crucial because traditional egg-based vaccines take approximately six months to produce, which is not ideal for responding quickly to fast-mutating influenza viruses.
Recombinant technology is also gaining traction in influenza vaccine development. During the 2017-2018 flu season, the effectiveness rate of the recombinant flu vaccine (Flublok) was about 53%, compared to a 47% effectiveness rate for traditional vaccines. This higher effectiveness rate is driving the increasing adoption of recombinant vaccines. Additionally, the success of mRNA technology in COVID-19 vaccines, such as Pfizer-BioNTech’s vaccine with about 95% effectiveness, has opened new possibilities for similar technology in flu vaccines.
These technological advancements are reshaping the influenza vaccine market, offering the potential for more effective and rapidly produced vaccines. This trend is likely to have a significant impact on the global influenza vaccine market, driving growth and improving public health outcomes.
Inactivated Influenza Vaccine (IIV) Generate Half of the Revenue Share
The Inactivated Influenza Vaccine (IIV) segment holds a significant market share of 89.60% in the global influenza vaccine market. This dominance is a result of several factors that contribute to the trust and widespread use of IIVs.
The projected growth of the IIV segment, with a Compound Annual Growth Rate (CAGR) of 11.15%, can be due to ongoing efforts in research and development. Scientists and manufacturers are continuously working to enhance vaccine efficacy by exploring advancements in adjuvant technology and developing more strain-specific vaccines. These efforts aim to improve the overall effectiveness of IIVs and provide better protection against evolving influenza strains.
Government initiatives promoting flu vaccination, particularly in developing countries, have fueled the growth of the IIV segment. Increasing awareness of the benefits of flu vaccination, coupled with government support, has encouraged more individuals to seek annual flu shots. This trend is further amplified by the heightened focus on flu vaccination campaigns following recent influenza outbreaks and the recognition of the importance of proactive prevention.
North America: Leading the Global Influenza Vaccine Market
North America, particularly the United States, stands at the forefront of the global influenza vaccine market, commanding a significant market share of over 43%. This remarkable dominance can be owing to several key factors that have contributed to the region’s leadership in influenza vaccination.
North America boasts a well-established healthcare infrastructure, which plays a crucial role in the widespread availability and accessibility of influenza vaccines. The region’s healthcare system has been effective in raising public awareness about the importance of influenza vaccination, resulting in a high level of acceptance and uptake among the population.
Government support and initiatives have played a pivotal role in driving the success of influenza vaccination in North America. Robust vaccination programs, backed by substantial funding, have been implemented to ensure the population has access to vaccines. Notably, the Centers for Disease Control and Prevention (CDC) in the United States has been actively involved in promoting and coordinating influenza vaccination efforts, leading to significant progress.
During the 2019-2020 flu season, the United States achieved a noteworthy milestone, with approximately 48.4% of the adult population receiving a flu vaccine, highlighting the region’s commitment to public health.
For The Full Report, Please Follow This Link- https://www.astuteanalytica.com/industry-report/influenza-vaccine-market
North America, particularly the United States, has demonstrated a strong focus on research and development in the field of influenza vaccines. The U.S. Department of Health and Human Services has made substantial investments, surpassing $1 billion, in advancing cell-based influenza vaccine technology. This commitment to innovation and technological advancements further solidifies the region’s position as a leader in the global influenza vaccine market.
Top Players in the Global Influenza Vaccine Market
- Abbott Laboratories
- Emergent BioSolutions Inc
- Emergex Vaccines Holding Limited
- GSK plc
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi SA
- CSL Limited
- Sinovac Biotech Ltd.
- SK bioscience Co., Ltd.
- Viatris Inc.
- Other Prominent Players
Market Segmentation Overview
- Inactivated influenza vaccine (IIV)
- Live-attenuated influenza vaccine (LAIV)
- Egg Based
- Cell Culture-Based
By Route of Administration
By Age Group
By Distribution Channel
- Hospitals & Pharmacies
- Government Suppliers
- North America
- The U.S.
- Western Europe
- The UK
- Rest of Western Europe
- Eastern Europe
- Rest of Eastern Europe
- Asia Pacific
- Australia & New Zealand
- South Korea
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- Rest of MEA
- South America
- Rest of South America
Get a Free Sample Report Here- https://www.astuteanalytica.com/request-sample/influenza-vaccine-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
𝐆𝐞𝐭 𝐢𝐧 𝐭𝐨𝐮𝐜𝐡 𝐰𝐢𝐭𝐡 𝐮𝐬
𝐏𝐡𝐨𝐧𝐞 𝐧𝐮𝐦𝐛𝐞𝐫: +𝟏𝟖𝟖𝟖𝟒𝟐𝟗𝟔𝟕𝟓𝟕
𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.astuteanalytica.com/